Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
about
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancerOnce versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerSubcutaneous unfractionated heparin for the initial treatment of venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolismOnce versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismVTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSystems for grading the quality of evidence and the strength of recommendations II: pilot study of a new systemOvarian cancer, the coagulation pathway, and inflammationPulmonary thrombo-embolism in pregnancy: diagnosis and managementDeep Venous Thrombosis: An Interventionalist's ApproachA systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyEfficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis.The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trialsAn economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleedingDosing and monitoring of low-molecular-weight heparins in special populations.EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.Optimal management of high-risk T1G3 bladder cancer: a decision analysisUnfractionated heparin: focus on a high-alert drug.Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).Heparin in interventional radiology: a therapy in evolutionThe Treatment of Venous Thromboembolism in Patients with Cancer.Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.Impact of venous thromboembolism and anticoagulation on cancer and cancer survivalHealth system capacity and infrastructure for adopting innovations to care for patients with venous thromboembolic diseaseAnticoagulation for venous thromboembolism. What are the current options?New developments in the prevention and treatment of venous thromboembolism.Differentiation of the low-molecular-weight heparins.Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.Once versus twice daily LMWH for the initial treatment of venous thromboembolism.The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Hypercoagulable state testing and malignancy screening following venous thromboembolic events.
P2860
Q24193871-3D121F4C-123E-4CB0-8D31-CC275585F176Q24201186-E2FDD30B-9415-4964-8FFC-2E3F2343CBECQ24234155-76B35E73-2D7F-47FD-9C44-BB6E216088A6Q24235193-5854F993-C055-4ADC-B413-C850D8964120Q24236443-F63C1C07-FE8F-4629-8145-FF15B4CD73A9Q24240038-D1C232DA-5B3F-43D7-ADCB-A52BDB62DF8BQ24242243-01E13A08-89A7-4123-AA40-485DC4DD976DQ24244696-3F2DD2D5-AB1F-4CA6-A415-FABA0BAAEB98Q24246284-B48C30F8-98A3-4968-BC55-D8D0AB04AE8FQ24632982-1D7D24B3-4B89-486B-BEA0-2B694E9DB292Q24633053-B6EE67C6-CBE9-4B17-A550-D886FC8CA691Q24805951-9AE8C025-2A60-4C5C-A161-498E51169888Q24816796-9A8D7E69-561A-47EB-A2A6-77128C2E7A1AQ26749463-F748DFC9-07E1-4FF9-93A1-83C461DCBAFEQ26827598-3D7807A9-270B-44A7-9AA1-D37BF62955E3Q26995027-A313FF7E-DE5C-4DC9-A43F-4F759D3F267AQ27690235-AEDA65F2-F98F-4A16-B89E-C7D16715A6D4Q28296482-48877153-8E37-4E69-84D2-7DA5EDA2068FQ28475640-95070376-C54F-4D36-8D86-D9A3D3302AC8Q32049893-B446D6B1-CA3D-4DAE-86C0-95D1030AA161Q33249813-BF0EB2DD-D32C-4603-B27C-F397329B59F8Q33300413-737D7716-5DC9-4C18-8AEB-77E778B66ACDQ33362322-7EB2AFCC-4CF4-4106-8695-0199A4EDC28CQ33370106-D44FC9B1-034A-43DD-88E4-5D8F493C7762Q33372266-7F65AD16-8C04-4218-ABDD-EDB14BDDD9A0Q33380863-6153056A-D617-4798-81EF-83E229756EA9Q33389637-3DEC0C4A-D892-43A5-9A1E-5EED5926B72CQ33394179-4ECC7796-5FFF-4A8C-8471-B8C2DDFA7F21Q33435329-4EED5F00-7958-4172-8FB7-11543565FF8CQ33442494-46B8049A-2B7B-4CEC-B08D-6C3EB405F47DQ33561203-8AFBC06C-3B76-4FE1-A35E-78B4E5D2CECAQ33856776-6093A4F1-9A6C-4177-8569-07AFFD162388Q34054473-FA90C8B6-314D-4D0D-8A01-D5391DEB3C4FQ34278849-20FE1E9F-4666-4957-BA10-9739DD4DBA4CQ34278856-9B676126-55D7-447C-9C03-F8BD8E62C754Q34688195-B335EBB8-5C83-49AF-A00F-2C5D9659E203Q35048657-F7400F6D-29CB-4945-8FF9-602825C974E5Q35095964-62D3958F-4AD6-46C4-BEF4-CC728E1D45F6Q35174604-1A502561-8E2B-4615-ABCB-E5A222FC560AQ35179215-28F99502-DBB5-49C1-A08A-E244C4F81407
P2860
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Low-molecular-weight heparins ...... randomized, controlled trials.
@en
type
label
Low-molecular-weight heparins ...... randomized, controlled trials.
@en
prefLabel
Low-molecular-weight heparins ...... randomized, controlled trials.
@en
P2093
P1476
Low-molecular-weight heparins ...... randomized, controlled trials.
@en
P2093
P304
P356
10.7326/0003-4819-130-10-199905180-00003
P407
P577
1999-05-01T00:00:00Z